We are excited to announce that our IVDR-CE marked MosaiQ AiPlex® Celiac Disease (CD) system is now available in the EU market and other geographies that recognize the CE mark (pending local registration in some countries).
Celiac Disease is a serious autoimmune disorder that affects approximately 1% of the global population. This condition primarily impacts the small intestine and occurs in genetically predisposed individuals. It is triggered by the ingestion of gluten, leading to an abnormal immune response.
Typically, the average time from the onset of Celiac Disease symptoms to diagnosis is 9.7 years, with a delay of 5.8 years from the initial doctor’s visit to diagnosis.1 This unacceptably long delay has a profound impact on patients’ quality of life. The MosaiQ AiPlex CD microarray immunoassay provides healthcare providers with an innovative solution to help reduce diagnostic delays and alleviate the unnecessary burden associated with celiac disease testing.
The MosaiQ AiPlex CD microarray contains key markers recommended by clinical guidelines. It is designed to deliver comprehensive diagnostic insights from a single sample and blood draw, while assisting laboratories in automating and simplifying the celiac disease diagnostic pathway.
Would you like to learn more about the MosaiQ AiPlex CD solution? Visit the MosaiQ AiPlex CD solution web page or contact us today.
1 Norström et al. BMC Gastroenterology 2011, 11:118
http://www.biomedcentral.com/1471-230X/11/118
